Effects of a Single-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban (PER977-P1)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Perosphere, Inc.
ClinicalTrials.gov Identifier:
NCT01826266
First received: April 3, 2013
Last updated: July 31, 2014
Last verified: July 2014
  Purpose

PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers. A dose of PER977 that reverses the effects of edoxaban on the pharmacodynamic (PD) biomarkers (point of care prothrombin time [PoC-PT]), and/or secondary biomarkers (thromboelastography reaction time [TEG-R]) will be identified.


Condition Intervention Phase
Anticoagulant Reversal.
Reversal of Edoxaban Induced Anticoagulation.
Drug: PER977, Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Phase I Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of a Single-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

Further study details as provided by Perosphere, Inc.:

Primary Outcome Measures:
  • • To evaluate the safety, tolerability, and plasma and urinary pharmacokinetics (PK) of a range of single intravenous (IV) doses of PER977 [ Time Frame: 7 months ] [ Designated as safety issue: Yes ]

Enrollment: 83
Study Start Date: July 2013
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: PER977-Dose 1
Dose titration
Drug: PER977, Placebo
Other Name: ciraparantag
Placebo Comparator: PER977-Dose 2
Dose Titration
Drug: PER977, Placebo
Other Name: ciraparantag
Placebo Comparator: PER977-Dose 3
Dose Titration
Drug: PER977, Placebo
Other Name: ciraparantag
Placebo Comparator: PER977-Dose 4
Dose Titration
Drug: PER977, Placebo
Other Name: ciraparantag
Placebo Comparator: PER977-Dose 5
Dose Titration
Drug: PER977, Placebo
Other Name: ciraparantag
Placebo Comparator: PER977-Dose 6
Dose Titration
Drug: PER977, Placebo
Other Name: ciraparantag
Placebo Comparator: PER977-Dose 7
Dose Titration
Drug: PER977, Placebo
Other Name: ciraparantag

Detailed Description:

Normal subjects will be dosed with PER977 alone and 1 week later, they will be given a single dose of edoxaban followed in 3 hours by a single IV dose of PER977. The purpose is to show safety and tolerability of PER977 alone and when combined with a NOAC (edoxaban). The study will also provide some insight into the doses that may be required to reverse a steady state edoxaban.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Adults age 18 to 45 years, inclusive
  2. Laboratory values (chemistry, complete blood count coagulation assessments) and urinalysis performed during screening up to 21 days prior to administration of study treatment are within normal limits.
  3. No clinically significant findings on 12-lead electrocardiogram (ECG) performed during screening.
  4. Body mass index (BMI) 18 to ≤32 kg/m2, inclusive
  5. Male subjects agree to use appropriate contraception (i.e., double barrier contraception such as a latex condom with spermicide with a female partner of child-bearing potential (a non-menopausal female who has not had one of the following: a) a hysterectomy (with or without oophorectomy), b) a bilateral oophorectomy without hysterectomy, or c) a medically documented ovarian failure) using a diaphragm or cervical cap or single barrier contraception if the female partner is using an intrauterine device or hormonal contraceptives or is sterilized; no barrier is required if the female partner has had a hysterectomy) when engaging in sexual activity during the course of the study. Moreover, male subjects should not donate sperm or attempt to impregnate a partner during the course of the study and for a period of 12 weeks following discharge from the study.
  6. Female subjects of non-childbearing potential (a menopausal female with the above 3 definitions for menopause) agree to use two forms of non-hormonal contraceptive (e.g. barrier methods [condom or diaphragm]) or intrauterine device for the duration of the study and for 30 days following the completion of the study. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
  7. Nonsmokers or nonusers of nicotine containing products within 3 months of dosing (occasional use of tobacco products within 30 days of dosing will be considered on a case-by-case basis)
  8. Subjects must understand and agree to comply with the requirements of the study and they must be willing to sign the informed consent form indicating voluntary consent to participate in the study prior to initiation of screening or study related activities.

Exclusion Criteria:

  1. History or current evidence of clinically significant cardiac, hepatic, renal, pulmonary, endocrine, neurologic, infectious, gastrointestinal, hematologic, or oncologic disease as determined by screening history, physical examination, laboratory test results or 12-lead ECG. History or current evidence of liver function tests greater than the upper limit of normal. History or current evidence of QTc Fridericia (QTcF) greater than normal (430±10 msec for males or 450±10 msec for females; average of three measurements).
  2. History of unexplained syncope
  3. Use of any drugs or substances known to be strong inhibitors or strong inducers of CYP3A4/5 transporters of p-glycoprotein within 28 days prior to the first dosing (Appendix 15.2 and Appendix 15.3)
  4. History of major bleeding, trauma, surgical procedure of any type, or vaginal delivery within six months prior to screening
  5. History of peptic ulcer, gastrointestinal bleeding (including hematemesis, melena, rectal bleeding) or bleeding from hemorrhoids within six months prior to screening
  6. History of minor bleeding episodes such as epistaxis, rectal or hemorrhoidal bleeding (spots of blood on toilet paper) or gingival bleeding within 3 months prior to screening
  7. Personal or family history of clotting disorder or abnormality, excessive bleeding, thrombovascular disease or any hematologic disorder involving platelets or clotting abnormalities or any condition requiring treatment with transfusions, anticoagulants or platelet inhibitors
  8. Females with a history of dysfunctional uterine bleeding, including history of menorrhagia (heavy menstrual bleeding), metrorrhagia or polymenorrhea or current use of hormonal contraceptives.
  9. Pregnant or breast-feeding
  10. Administration of any blood product or anticoagulant within 3 months prior to study entry or any non-steroidal anti-inflammatory drug or cyclooxygenase inhibitor within 2 weeks prior to screening
  11. Taking any type of chronic medication within the 4 weeks prior to study entry
  12. Positive serologic test for human immunodeficiency virus (HIV), Hepatitis C virus (HCV), or Hepatitis B surface antigen (HBsa)
  13. Use of any of the following medications in the 4 weeks prior to study entry: rifampin, dronedarone, ketoconazole, verapamil, amiodarone, quinidine, clopidogrel, oral anticoagulants, or other agent known to interact with edoxaban
  14. Participation in any study with an investigational compound or device within 30 days prior to signing informed consent
  15. Active drug, alcohol or nicotine use or dependence or any condition that, in the opinion of the Investigator, would interfere with adherence to study protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01826266

Locations
United States, North Carolina
Duke Clinical Research, Unit 200
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Perosphere, Inc.
Investigators
Principal Investigator: Robert Noveck, MD, PhD Duke Clinical Research Unit
  More Information

No publications provided

Responsible Party: Perosphere, Inc.
ClinicalTrials.gov Identifier: NCT01826266     History of Changes
Other Study ID Numbers: PER977-01-001, PER977-01
Study First Received: April 3, 2013
Last Updated: July 31, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Perosphere, Inc.:
PER977
Activated partial thromboplastin time
Assessment
D-dimer
Enrollment
Investigational drug
Investigational treatment
Period
Premature subject withdrawal
Prothrombin time
Randomization number
Study discontinuation
Study drug
Subject number
Study treatment
Thromboelastography-reaction time

ClinicalTrials.gov processed this record on September 14, 2014